bexarotene has been researched along with arsenic trioxide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, MH; Flamm Honig, S; Hirschfeld, S; Ibrahim, A; Johnson, JR; O'Leary, JJ; Pazdur, R; White, RM; Williams, GA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for bexarotene and arsenic trioxide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for bexarotene and arsenic trioxide
| Article | Year |
|---|---|
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Topics: Anastrozole; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Bexarotene; Breast Neoplasms; Drug Approval; Female; Humans; Leukemia, Promyelocytic, Acute; Lymphoma, T-Cell, Cutaneous; Nitriles; Oxides; Paclitaxel; Tamoxifen; Tetrahydronaphthalenes; Triazoles; United States; United States Food and Drug Administration | 2001 |